Savara stock fell 4.66 percent ahead of the November FDA decision

Published on 10/04/2026 at 16:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Savara stock faces a November 22, 2026 FDA decision after Q2 adjusted EPS came in at USD -0.16 versus USD -0.14 consensus. Eight brokerages set a USD 10.00 average target.

SVRA, US8051111016, Illustration mit AI erstellt.

Savara Inc. (ISIN US8051111016) was last at USD 4.81 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 4.66 percent from the prior session. The key date ahead is November 22, 2026, when the FDA is expected to decide on Molbreevi for autoimmune pulmonary alveolar proteinosis, according to RTTNews on September 24, 2026.

FDA decision sets the next test

Molbreevi is the company name for molgramostim, an inhaled treatment candidate for a rare lung disorder in which surfactant accumulates in the lungs. RTTNews reported that the application is under review for a condition with substantial unmet medical need.

The regulatory timetable follows Savara's second-quarter update. The company's investor-relations page lists its Q2 2026 financial results and business update on August 11, 2026, while its August 24 release covered presentations of Phase 3 molgramostim results at the European Respiratory Society Congress, according to Savara.

Analyst targets stay above the quote

The analyst picture remains more constructive than the latest trading session. Eight brokerages give Savara a Moderate Buy consensus, with six Buy ratings, one Strong Buy and one Sell, while the average 12-month target is USD 10.00, according to MarketBeat on September 18, 2026.

That target stands USD 5.19 above the October 2 price, equivalent to 107.9 percent above the price. The contrast is material because the company reported adjusted Q2 2026 EPS of USD -0.16 against consensus of USD -0.14, a USD 0.02 miss, as MarketBeat reported on October 4, 2026.

MarketBeat also reported on October 4 that Wall Street Zen lowered Savara from Hold to Sell. That downgrade adds a more cautious counterpoint to the broader Moderate Buy consensus and keeps the November regulatory decision central to the investment case.

Stock remains below yearly high

SVRA's October 2 range was USD 4.76 to USD 5.16, with 2,652,411 shares traded. Its 52-week range was USD 3.34 to USD 7.01, and market capitalization stood at USD 985.7 million on the same date.